No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Express News | China Resources Sanjiu Says It Is Set to Become Tasly's Controlling Shareholder After the Transaction, China Resources to Become Tasly's Actual Controller
Express News | China Resources Sanjiu Medical & Pharmaceutical Says It Plans to Buy 28% Stake in Tasly
Tasly Pharmaceutical Group Co., Ltd Just Missed EPS By 7.6%: Here's What Analysts Think Will Happen Next
Tasly's 2024 Attributable Profit Declines 11%; Shares Slide 3%
Tianshili: A summary of the 2024 annual report of Tasly
